AnaptysBio Director's Planned Stock Sale Tied to RSU Tax Payment
Rhea-AI Filing Summary
Director Hollings Renton of AnaptysBio reported a sale of 3,015 shares of common stock at $23.97 per share on June 18, 2025. Following the transaction, Renton retains direct ownership of 4,965 shares.
Key details of the transaction:
- The sale was executed under a Rule 10b5-1 trading plan established on March 14, 2024
- The shares were sold to cover tax obligations related to the vesting of restricted stock units on June 15, 2025
- Total transaction value: approximately $72,269
This insider transaction represents a routine sale for tax purposes rather than a discretionary trading decision, as it was pre-planned through a 10b5-1 trading plan and specifically tied to RSU vesting obligations.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 3,015 shares
Net Sell
1 txn
Insider
RENTON HOLLINGS
Role
Director
Sold
3,015 shs ($72K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,015 | $23.97 | $72K |
Holdings After Transaction:
Common Stock — 4,965 shares (Direct)
Footnotes (2)
- F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024.
- F2. Shares sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units on June 15, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What was the purpose of ANAB Director Renton's stock sale in June 2025?
The shares were sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units that occurred on June 15, 2025.
Was ANAB Director Renton's stock sale part of a pre-planned trading arrangement?
Yes, the sale was executed pursuant to a Rule 10b5-1 trading plan that Director Renton adopted on March 14, 2024.